Efficacy and Safety of Rituximab in Connective Tissue Disease‐Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy
In CTD-associated TTP/TMA, B cells may affect pathology, and adding RTX to plasma exchange and GC therapy may be worth considering.
Authors
- Yasuyuki Todoroki (ORCID: https://orcid.org/0009-0003-4646-592X)
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Yoshino Inoue
- Naoaki Ohkubo (ORCID: https://orcid.org/0000-0003-2265-4104)
- Shunsuke Fukuyo (ORCID: https://orcid.org/0000-0001-7006-8826)
- Shingo Nakayamada (ORCID: https://orcid.org/0000-0002-2209-8454)
- Yusuke Miyazaki (ORCID: https://orcid.org/0009-0006-8032-0136)
- Hiroaki Tanaka (ORCID: https://orcid.org/0000-0002-6309-9234)
Institutions
- University of Occupational and Environmental Health Japan (JP)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1111/1756-185x.70292
- Citations
- 1
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Kowa Company
- University of Occupational and Environmental Health
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Chugai Pharmaceutical